Ticker

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (“Obsidian”) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today announced the completion of its previously announced transaction with Galera Therapeutics, Inc. (“Galera”). The combined company will operate under the name…

Profitability This table compares Galera Therapeutics and Eagle Pharmaceuticals' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Galera Therapeutics N/A N/A -99.34% Eagle Pharmaceuticals N/A N/A N/A Earnings and Valuation This table compares Galera Therapeutics and Eagle Pharmaceuticals"s top-line revenue, earnings per share and valuation. Gross